scholarly journals Experimental pain sensitivity in multiple system atrophy and Parkinson's disease at an early stage

2016 ◽  
Vol 20 (8) ◽  
pp. 1223-1228 ◽  
Author(s):  
V. Mylius ◽  
S. Pee ◽  
H. Pape ◽  
M. Teepker ◽  
M. Stamelou ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Multiple System Atrophy ◽  
Pain Sensitivity ◽  
Early Stage ◽  
Experimental Pain ◽  
Experimental Pain Sensitivity

scholarly journals Differentiation of Parkinson’s disease and Parkinsonism predominant multiple system atrophy in early disease stages by means of objective measurement in Susceptibility Weighted Imaging

2021 ◽  
Author(s):  
Qingguo Ren ◽  
Yihua Wang ◽  
Xiaomin Nan ◽  
Jianyuan Zhang ◽  
Xiangshui Meng ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Multiple System Atrophy ◽  
Signal Intensity ◽  
Early Stage ◽  
Region Of Interest ◽  
Final Diagnosis ◽  
Susceptibility Weighted Imaging ◽  
Lentiform Nucleus ◽  
Potential Marker

Abstract Background We have established radiological protocol and made morphological measurement of the lentiform nucleus (LN) and the signal intensity which we used to discriminate parkinsonism predominant multiple system atrophy (MSA-P) from Parkinson’s disease (PD). But we don’t know whether it works especially in early stage of MSA-P. This case-control study aimed to investigate whether the new measurement of the morphological and intensity changes in susceptibility weighted imaging (SWI) of the LN could discriminate MSA-P from PD in their early stage and controls. Methods We retrospectively enrolled patients with MSA-P, PD, and sex- and age-matched controls between January 2015 and July 2020 at the Movement Disorder Center who underwent brain MR scanning with SWI sequence. Two specialists at the center reviewed the medical records and made the final diagnosis, and two experienced neuroradiologists performed MRI image analysis based on a defined radiological protocol to conduct the region of interest (ROI) based morphological measurements of the LN and the signal intensity. Results A total of 17 patients with MSA-P, 17 patients with PD within 2 years of the disease duration and 17 controls were enrolled in this study. We found that patients with MSA-P had significant decreased size in the short line (SL, cSL), and the ratio of the SL and the long line (SLLr, cSLLr) compared with the patients with PD and with the controls (P < 0.05). Combining these four indexes, this finding had a sensitivity of 58.8% and a specificity of 100% to distinguish MSA-P from PD. Conclusions As compared to PD and control subjects, the MSA-P patients are characterized by narrowing morphology of the posterior region of LN. The quantitative morphological change is a possible potential marker to differentiate MSA-P from PD in the early stage.

scholarly journals Serotonin Transporter Availability in Early Stage Parkinson’s Disease and Multiple System Atrophy

2014 ◽  
Vol 2014 ◽  
pp. 1-4 ◽  
Author(s):  
S. R. Suwijn ◽  
H. W. Berendse ◽  
C. V. M. Verschuur ◽  
R. M. A. de Bie ◽  
J. Booij
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Multiple System Atrophy ◽  
Dopamine Transporter ◽  
Serotonin Transporter ◽  
Disease Duration ◽  
Early Stage ◽  
Spect Imaging ◽  
Parkinsonian Syndrome ◽  
Atypical Parkinsonian Syndrome

Background. Differentiating Parkinson’s disease (PD) from multiple system atrophy (MSA) can be challenging especially early in the course of the disease. Previous studies have shown that midbrain serotonin transporter (SERT) availability in patients with established MSA was significantly lower compared to PD. It is unknown if this is also true for early-stage patients. Methods. 77 early-stage, untreated PD patients were recruited between 1995 and 1998, underwent [123I]β-CIT SPECT imaging, and were followed for at least five years. 16 patients were lost to followup, and in 4 the diagnosis was changed to another atypical parkinsonian syndrome, but not in MSA. In 50 patients, the PD diagnosis was unchanged at followup. In seven patients, the diagnosis was changed to MSA at followup. We retrospectively assessed baseline midbrain SERT availability as well as midbrain SERT-to-striatal dopamine transporter (DAT) ratios. Results. No difference in baseline [123I]β-CIT SERT availability was found. The midbrain SERT-to-striatal DAT ratio for whole striatum was significantly lower in patients with PD compared to MSA (P=0.049). However, when adjusting for the disease duration at imaging this difference is not significant (P=0.070). Conclusion. Midbrain SERT availability is not different between early-stage PD and MSA. Therefore, SERT imaging is not useful to differentiate between early PD and MSA.

Cutaneous Sympathetic Vasoconstrictor Function in Multiple System Atrophy and Parkinson's Disease

2004 ◽  
Vol 35 (03) ◽  
Author(s):  
G Wasner ◽  
P Remien ◽  
C Guballa ◽  
M Hirschner ◽  
A Binder ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Multiple System Atrophy

Association of the Non-Motor Burden with Patterns of Striatal Dopamine Loss in de novo Parkinson’s Disease

2020 ◽  
Vol 10 (4) ◽  
pp. 1541-1549
Author(s):  
Seok Jong Chung ◽  
Sangwon Lee ◽  
Han Soo Yoo ◽  
Yang Hyun Lee ◽  
Hye Sun Lee ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
De Novo ◽  
Early Stage ◽  
Striatal Dopamine ◽  
Motor Deficits ◽  
Dopamine Depletion ◽  
Severe Motor ◽  
Severe Group ◽  
Striatal Dopamine Depletion

Background: Striatal dopamine deficits play a key role in the pathogenesis of Parkinson’s disease (PD), and several non-motor symptoms (NMSs) have a dopaminergic component. Objective: To investigate the association between early NMS burden and the patterns of striatal dopamine depletion in patients with de novo PD. Methods: We consecutively recruited 255 patients with drug-naïve early-stage PD who underwent 18F-FP-CIT PET scans. The NMS burden of each patient was assessed using the NMS Questionnaire (NMSQuest), and patients were divided into the mild NMS burden (PDNMS-mild) (NMSQuest score <6; n = 91) and severe NMS burden groups (PDNMS-severe) (NMSQuest score >9; n = 90). We compared the striatal dopamine transporter (DAT) activity between the groups. Results: Patients in the PDNMS-severe group had more severe parkinsonian motor signs than those in the PDNMS-mild group, despite comparable DAT activity in the posterior putamen. DAT activity was more severely depleted in the PDNMS-severe group in the caudate and anterior putamen compared to that in the PDMNS-mild group. The inter-sub-regional ratio of the associative/limbic striatum to the sensorimotor striatum was lower in the PDNMS-severe group, although this value itself lacked fair accuracy for distinguishing between the patients with different NMS burdens. Conclusion: This study demonstrated that PD patients with severe NMS burden exhibited severe motor deficits and relatively diffuse dopamine depletion throughout the striatum. These findings suggest that the level of NMS burden could be associated with distinct patterns of striatal dopamine depletion, which could possibly indicate the overall pathological burden in PD.

Gene expression analysis in modeling Parkinson’s disease

2020 ◽  
pp. 103-104
Author(s):  
М.М. Руденок ◽  
А.Х. Алиева ◽  
А.А. Колачева ◽  
М.В. Угрюмов ◽  
П.А. Сломинский ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Early Stage ◽  
Systemic Disease ◽  
Molecular Genetic ◽  
Presymptomatic Stage ◽  
Whole Transcriptome Analysis ◽  
Whole Transcriptome ◽  
The Brain ◽  
Transcriptome Level

Несмотря на очевидный прогресс, достигнутый в изучении молекулярно-генетических факторов и механизмов патогенеза болезни Паркинсона (БП), в настоящее время стало ясно, что нарушения в структуре ДНК не описывают весь спектр патологических изменений, наблюдаемых при развитии заболевания. В настоящее время показано, что существенное влияние на патогенез БП могут оказывать изменения на уровне транскриптома. В работе были использованы мышиные модели досимптомной стадии БП, поздней досимптомной и ранней симптомной (РСС) стадиями БП. Для полнотранскриптомного анализа пулов РНК тканей черной субстанции и стриатума мозга мышей использовались микрочипы MouseRef-8 v2.0 Expression BeadChip Kit («Illumina», США). Полученные данные указывают на последовательное вовлечение транскриптома в патогенез БП, а также на то, что изменения на транскриптомном уровне процессов транспорта и митохондриального биогенеза могут играть важную роль в нейродегенерации при БП уже на самых ранних этапах. Parkinson’s disease (PD) is a complex systemic disease, mainly associated with the death of dopaminergic neurons. Despite the obvious progress made in the study of molecular genetic factors and mechanisms of PD pathogenesis, it has now become clear that violations in the DNA structure do not describe the entire spectrum of pathological changes observed during the development of the disease. It has now been shown that changes at the transcriptome level can have a significant effect on the pathogenesis of PD. The authors used models of the presymptomatic stage of PD with mice decapitation after 6 hours (6 h-PSS), presymptomatic stage with decapitation after 24 hours (24 h-PSS), advanced presymptomatic (Adv-PSS) and early symptomatic (ESS) stages of PD. For whole transcriptome analysis of RNA pools of the substantia nigra and mouse striatum, the MouseRef-8 v2.0 Expression BeadChip Kit microchips (Illumina, USA) were used. As a result of the analysis of whole transcriptome data, it was shown that, there are a greater number of statistically significant changes in the tissues of the brain and peripheral blood of mice with Adv-PSS and ESS models of PD compared to 6 h-PSS and 24 h-PSS models. In general, the obtained data indicate the sequential involvement of the transcriptome in the pathogenesis of PD, as well as the fact that changes at the transcriptome level of the processes of transport and mitochondrial biogenesis can play an important role in neurodegeneration in PD at an early stage.

Sign in / Sign up

Export Citation Format

Share Document